Of these, 30% are oncological projects and 20% are infectious diseases and cardiology.
Turnkey projects continue to be priority areas for OCT business. This spring, another medicinal product (eye drops for treatment of ocular inflammation following cataract surgery) investigated by OCT was entered into the Russian State Register of Medicinal Products. When the phase III clinical trial of the drug was completed, OCT proceeded with the registration process.
‘The Eastern Europe with its fast enrollment rates and access to large populations is always attractive for international sponsors. For example, now we are conducting a phase III clinical trial in subjects with metastatic or recurrent lung cancer. We’ve managed to enroll 50% of the patients 3 months earlier than originally planned. This fact is particularly impressive considering the study phase and indication,’ says OCT Clinical Operations Director Irina Petrova. III phase trials account for about one third of all projects conducted by the company.
OCT ranked first in the list of all Russian CROs with the highest number of authorizations for clinical and bioequivalence studies in 2016 and was among the TOP 25 Life Science Innovators-2017 according to Global Health and Pharma magazine.